Suppr超能文献

初始中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值可作为不可手术局部晚期非小细胞肺癌患者的预后标志物。

Initial neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with inoperable locally advanced non-small-cell lung cancer.

机构信息

Radiation Oncology Department of Thoracic Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District Shenyang, Liaoning Province 110042, PR China.

出版信息

Biomark Med. 2020 Oct;14(14):1341-1352. doi: 10.2217/bmm-2019-0583. Epub 2020 Aug 18.

Abstract

To determine whether pretreatment of neutrophil-to-lymphocyte ratio (NLR) or platelet-to-lymphocyte ratio (PLR) has a prognostic value in patients with inoperable locally advanced non-small-cell lung cancer. A total of 167 patients between 2013 and 2016 were analyzed retrospectively. Appropriate cut-off values for initial NLR (3.06) and PLR (168.03) were determined by receiver operating characteristic curves. High NLR (p < 0.001 and p < 0.001) was related to poor overall survival (OS) and progression-free survival (PFS) via univariate analysis. Multivariable analysis showed that NLR can independently influence OS (hazard ratio: 1.570; p = 0.012) and PFS (hazard ratio: 1.471; p = 0.023). PLR did not correlate with OS or PFS. Pretreatment of NLR could independently predict the prognosis of inoperable locally advanced non-small-cell lung cancer patients, while pretreatment of PLR does not have prognostic value.

摘要

为了确定中性粒细胞与淋巴细胞比值(NLR)或血小板与淋巴细胞比值(PLR)预处理在不可手术局部晚期非小细胞肺癌患者中的预后价值。回顾性分析了 2013 年至 2016 年间的 167 例患者。通过受试者工作特征曲线确定初始 NLR(3.06)和 PLR(168.03)的适当截止值。单因素分析显示,高 NLR(p<0.001 和 p<0.001)与总生存(OS)和无进展生存(PFS)不良相关。多变量分析表明,NLR 可独立影响 OS(风险比:1.570;p=0.012)和 PFS(风险比:1.471;p=0.023)。PLR 与 OS 或 PFS 无关。NLR 预处理可独立预测不可手术局部晚期非小细胞肺癌患者的预后,而 PLR 预处理无预后价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验